What did AFT Pharmaceuticals Limited announce?

AFT Pharmaceuticals Limited (NZX: AFT) filed “Maxigesic IV Licensed for Japan” with NZX on 27 September 2026, as an operational update announcement.

From the announcement:“AFT Pharmaceuticals (NZX: AFT; ASX: AFP), today announces that they have entered into an exclusive development, license and supply agreement with MIKASASEIYAKU CO., LTD.”
When was it filed?
27 September 2026
Where is the original?
NZX announcement
AFT Pharmaceuticals Limited logo

Maxigesic IV Licensed for Japan

Operational Update27 September 2026AFTHealthcare

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in
New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com



28

th

September 2026


Maxigesic IV Licensed for Japan


AFT Pharmaceuticals (NZX: AFT; ASX: AFP), today announces that they have entered

into an exclusive development, license and supply agreement with MIKASASEIYAKU

CO., LTD. ("Mikasa") for the development and commercialization of AFT's intravenous

fixed-dose combination analgesic, Maxigesic® IV (also known as Combogesic® IV)

in Japan, the third largest pharma market in the world.

Under the agreement, AFT grants Mikasa an exclusive license to seek marketing

authorization for and commercialize the product throughout Japan. AFT will be

responsible for developing and supplying the product, while Mikasa will lead

regulatory submissions to Japan's Pharmaceuticals and Medical Devices Agency

(PMDA), pursue marketing authorization, and development and commercialization

of the product in the Japanese market.

Maxigesic® IV is a proprietary, non-opioid injectable combination of paracetamol

(1000 mg) and ibuprofen (300 mg) developed by AFT for the management of pain.

The collaboration is intended to make this treatment option available to patients

and healthcare providers in Japan.

Under the agreement, AFT will receive an upfront license fee, development

milestones linked to regulatory submission progress and reimbursement pricing in

Japan, with Royalties earned on commercial sales following launch. AFT will also be

supplying the finished product to Mikasa. AFT was assisted with this licensing

agreement in Japan by Shin Nippon Biomedical Laboratories Ltd (TSE: 2395).

Released for, and on behalf of, AFT Pharmaceuticals Limited by Stuart Houliston,

Chief Financial Officer.


For more information:

Investors Media

Dr Hartley Atkinson Richard Inder

Managing Director The Project

AFT Pharmaceuticals Tel: +64 21 645 643

Tel: +64 9488 0232



About AFT Pharmaceuticals

AFT is a growing New Zealand based multinational pharmaceutical company that

develops, markets, and distributes a broad portfolio of pharmaceutical products

across a wide range of therapeutic categories which are distributed across all major

pharmaceutical distribution channels: over the counter (OTC), prescription and

2

hospital. Our product portfolio comprises both proprietary and in -licensed products,

and includes patented, branded, and generic drugs. Our business model is to

develop and in -license products for in our markets of Australia, New Zealand,

Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-

license our products to local licensees and distributors to over 125 countries around

the world. For more information about the company, visit our

website www.aftpharm.com.


About MIKASASEIYAKU CO., LTD.

 https://www.mikasaseiyaku.co.jp/

Guided by its corporate philosophy, “Contributing to society through the healthcare

industry, with pharmaceuticals at its core,” Mikasa has been engaged since its

founding in the research and development, manufacturing, and marketing of

pharmaceuticals, primarily in the field of orthopaedics. Mikasa will continue to

contribute to people’s health and the realization of a prosperous society through the

provision of pharmaceutical products.

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.